Cheryl A. Fitch

Zinc inhibits the nuclear translocation of the tumor suppressor protein p53 and protects cultured human neurons from copper-induced neurotoxicity.

High concentrations of the trace metal zinc (Zn) have previously been shown to provide transient protection of cells from apoptotic death. The molecular mechanisms responsible for this protection are not known. Thus, this work explored the ability of Zn to protect human neurons in culture (NT2-N) from Cu-mediated death and tested the hypotheses that the tumor-suppressor protein p53 plays a role in Cu-induced neuronal death and is part of the mechanism of Zn protection. Copper toxicity (100 µM) resulted in significant apoptotic neuronal death by 12 h. Addition of 100 µM Zn to Cu-treated cells increased neuronal death. However, the addition of 700 µM Zn to Cu-treated cells resulted in neuronal viability that was not different from untreated controls through 24 h. p53 mRNA abundance, while increased by the addition of Cu and 100 µM Zn, was decreased to 50% of control with the addition of 500 µM Zn in Cu-treated cells, and to 10% of control with 700 µM Zn. Consistent with its role as a transcription factor, both Western analysis and immunocytochemistry showed significant increases in nuclear p53 protein levels in Cu toxicity. The role of p53 in Cu-mediated apoptosis was further confirmed by elimination of apoptosis in Cu-treated cells that had been transfected with a dominant-negative p53 construct to prevent p53 expression. Furthermore, the addition of 500–700 µM Zn prevented the movement of p53 into the nucleus suggesting that Zn not only protects neurons from Cu toxicity by regulating p53 mRNA abundance but also by preventing the translocation of p53 to the nucleus.

Antagonism of Oxytocin Prevents Suckling- and Estradiol-Induced, But Not Progesterone-Induced, Secretion of Prolactin

In female rats, estradiol (E(2)) and suckling induce prolactin (PRL) secretion. This involves inhibition of hypothalamic dopaminergic tone and stimulation by a PRL-releasing hormone, possibly oxytocin (OT). Infusing an OT antagonist (OTA) i.v., we evaluated the role of OT on suckling- and E(2)-induced PRL secretion. Three days after parturition at 0900 h, lactating dams were fitted with 24-h osmotic minipumps filled with saline or OTA. On d 5 of lactation, pups were separated from their dams for 6 h. Immediately or 20 min after the resumption of suckling, dam trunk blood was collected. Also, ovariectomized (OVX) rats were treated with E(2) (OVE) and OTA at 1000 h on d 1. Blood samples were obtained from 1300 to 2100 h on d 2 for PRL measurements. Additionally, OVX rats were evaluated on d 2 after receiving progesterone (P(4)). OTA blocked suckling and E(2)-induced release of PRL but not that induced by E(2)+P(4). Pups from treated dams failed to gain weight when allowed to nurse for 20 min on d 5 but gained more than 7 g when nursed on d 7 of lactation, indicating that the OTA was active 48 h later. Western blot analysis showed that E(2) treatment increased OT receptors in the anterior pituitary when compared with OVX animals. No further increase was observed in response to the P(4), suggesting that the enhancing effect of P(4) on E(2)-induced PRL release may act through mechanisms independent of OT. These data demonstrate the role of OT in the control of suckling and steroid-induced PRL secretion.

Effect of altered thyroid hormone status on rat brain ferritin H and ferritin L mRNA during postnatal development

The iron binding protein ferritin is a heterogeneous mix of 24 heavy (H) and light (L) subunits. The H subunit is associated with iron utilization, while the L subunit is responsible for iron storage. Examination of the developmental pattern of mRNA abundance in rat brain revealed that ferritin L mRNA is highest at birth and declines during the first postnatal week. A similar decline was seen in ferritin H mRNA, but was followed by an increase in ferritin H mRNA in the second postnatal week which continued through postnatal day 21. The pattern of H mRNA regulation is similar to that in previous reports of total ferritin protein in the developing rat brain and is consistent with the fact that brain ferritin is predominately ferritin H. The effect of thyroid hormone on the developmental regulation of ferritin mRNAs was examined by the subcutaneous injection of a single dose of exogenous thyroxine (T(4); 2 microg/g) on postnatal day 1. Hypothyroidism was induced in pregnant dams with propylthiouracil (PTU; 0.05% in drinking water) from gestational day 7. Northern analysis from postnatal days 2-21 showed that T(4) increased ferritin H mRNA throughout development, while ferritin L mRNA was decreased compared to age-matched controls. PTU treatment decreased ferritin H and increased L mRNA in the later stages (days 14-21) of development. Given the distinct functions of ferritin H and L this suggests a role for thyroid hormone in the ability of the brain to regulate stored vs. utilizable iron during critical periods of development.

REGULATION OF METALLOTHIONEIN-3 MRNA BY THYROID HORMONE IN DEVELOPING RAT BRAIN AND PRIMARY CULTURES OF RAT ASTROCYTES AND NEURONS

Metallothionein-3 (MT-3) is a brain specific member of the MT family. Unlike other members of this family, MT-3 has been shown to act as a neuronal growth inhibitory factor. MT-3 mRNA abundance increases throughout the developmental period, reaching adult levels by postnatal day 21. The role of thyroid hormone in the developmental regulation of MT-3 mRNA was tested because thyroid hormone is known to regulate brain gene expression. Furthermore, gestational hypothyroidism results in developmental brain abnormalities. Hypothyroidism was induced in pregnant dams by the administration of PTU from gestational day 7, resulting in a 4- to 6-fold increase in pup MT-3 mRNA abundance on the day of birth (day 0) and on postnatal day 3. Normal pups did not reach this level of brain MT-3 mRNA until postnatal day 21. Administration of thyroxine (T(4), 2 microg/g) to pups on postnatal day 1 or day 20 resulted in a decrease in MT-3 mRNA abundance on postnatal day 21, regardless of when the injection was given. Furthermore, addition of T(4) to primary cultures of brain (olfactory bulb) astrocytes and neurons from 4-day-old rats resulted in a significant decrease in MT-3 mRNA in 24 h. Given the neuronal growth inhibitory function of MT-3, these data suggest that MT-3 may play a role in the CNS-related consequences of hypo- and hyperthyroidism during development.

Regulation of neuropeptide Y mRNA and peptide concentrations by copper in rat olfactory bulb

Neuropeptide Y is highly abundant in both the peripheral and central nervous systems and is known to have diverse functions including regulation of feeding behavior, blood pressure, circadian rhythms, reproductive behavior and the response to stress. Northern analysis showed that copper deficiency increased brain NPY mRNA abundance particularly in the olfactory bulb (OB). These increases were not accompanied by alterations in food intake or blood pressure. After 4 weeks of a copper-restricted diet, OB copper concentrations decreased to 44% of control and NPY mRNA increased 1.5-fold. Addition of a copper chelator to the restricted diet, resulted in a two-fold increase in OB NPY mRNA over copper adequate controls. These results were confirmed in primary cultures of OB neurons suggesting that the regulation of NPY mRNA is at the level of the bulb rather than by a hormonal or other copper-regulated factor external to the OB. Immunoreactive NPY (IR-NPY) levels were not, however, increased following the 4 weeks of copper deficiency. Addition of the chelator resulted in a 1.4-fold increase in IR-NPY that, while statistically significant, was not proportional to the two-fold increase in NPY mRNA in the same study. This may suggest that copper deficiency inhibits the translational mechanisms responsible for the synthesis of NPY or that NPY is exported from the bulb in copper deficiency.

Zinc Regulation of Cobalt-Induced Apoptosis in Cultured Human Neurons

While it is clear that hypoxic-ischemic injury leads to neuronal death, the type of cell death and the molecular mechanisms involved are not fully understood. This study was designed to test the hypothesis that cobalt-induced hypoxia induces neuronal apoptosis and that high concentrations of the nutrient zinc protects neurons. Treatment of cultured postmitotic human neurons (NT2-N) with cobalt to mimic hypoxia resulted in a significant reduction in the number of viable NT2-N neurons. Cellular and nuclear morphology suggested that hypoxic NT2-N neurons die as a result of apoptosis. Northern analysis and immunocytochemistry revealed increases in p53 mRNA and p53. Cobalt also resulted in translocation of p53 to the nucleus of apoptotic neurons. Treatment with high concentrations of zinc (700 μM) not only reduced the morphological evidence of apoptosis, but also appeared to inhibit nuclear translocation of p53. Hsp 70, a chaperone protein that has been associated with cellular protection, was increased by cobalt. Additional increases in the nuclear translocation of Hsp 70 were observed following zinc treatment of hypoxic neurons suggesting that at high concentrations zinc may act to protect neurons from cobalt-induced hypoxia by decreasing nuclear p53 and increasing Hsp 70 in vitro.

Regulation of mitochondrial cytochromeb mRNA by copper in cultured human hepatoma cells and rat liver

Copper overload and deficiency are known to cause morphological and functional mitochondrial abnormalities. The reverse transcriptase-polymerase chain reaction (RT-PCR)-based method of differential display of mRNA was used to identify genes with altered expression in cultured human hepatoma cells (Hep G2) exposed to increasing concentrations of copper (0–100 ΜM, 24 h). Copper regulation of a cloned PCR product, identified as the gene for the mitochondrially encoded cytochromeb, was confirmed by Northern analysis andin situ hybridization. Copper toxicity increased cytochromeb mRNA abundance up to 3.6-fold, and copper chelation reduced it by 50%. Hepatic cytochromeb mRNA was also increased in rats fed a high-copper diet. Thapsigargin treatment resulted in a significant increase in cytochromeb mRNA, suggesting that an increase in intracellular calcium may be involved in the mechanism of copper action. Furthermore, although cyclohexamide (CHX) alone did not increase cytochromeb mRNA, the addition of CHX and copper resulted in a sixfold increase. These data suggest a role for cytochromeb in the response to increases or decreases in hepatic copper.

Effects of the estrous cycle stage on the prolactin secretory response to dopamine in vitro

Dopamine (DA) will both stimulate and inhibit prolactin (PRL) secretion from the anterior pituitary gland in vitro and in vivo. The present study was designed to determine if there are selected times during the estrous cycle of the rat when one function is favored over the other. Anterior pituitary glands collected on diestrus-1 (D1), diestrus-2 (D2), the morning of proestrus (Pro-AM), the afternoon of proestrus (Pro-PM), and estrus (E) were enzymatically dissociated and placed in monolayer culture. On the fourth day in culture, cells were challenged for 10, 20, 30, 60, 120, 180, or 240 min with media alone or media containing either 100 pM or 1 μM DA. The concentration of PRL in the media was determined by radioimmunoassay. Regression analysis revealed that in the absence of DA, PRL secretion from cultured cells differed significantly depending on the stage of the estrous cycle during which they were obtained. Cells obtained during the morning of diestrus-2 secreted PRL at the greatest rate compared to other stages of the cycle. When all stages were compared, the rates of PRL secretion were: D2>E>D1>Pro-AM>Pro-PM (each significantly different from the others,P<0.01). By 20–30 min of exposure to 100 pM DA, the rate of PRL secretion from cells obtained during each stage of the cycle was significantly enhanced. This enhanced secretion persisted in cells obtained during D2 and Pro-PM but was short-lived in cells obtained during other stages. No inhibition of PRL secretion was induced by this dose of DA. PRL secretion was inhibited when treated with 1 μM DA in cells obtained at all stages of the estrous cycle. Inhibition was more prolonged in cells obtained on D1, D2, and Pro-AM. DA was least effective as an inhibitor of PRL secretion in cells obtained during Pro-PM and E. Prior to inhibiting PRL secretion in cells obtained during Pro-PM, 1 μM DA rapidly stimulated PRL secretion. This effect persisted for 60 min. These data suggest that in the absence of DA, the dynamics of PRL secretion from anterior pituitary cells in vitro differ depending on the stage of the estrous cycle during which the cells were obtained. Moreover, the in vivo environment of the cell determines the direction and magnitude of the PRL-secretory response to DA.